To include your compound in the COVID-19 Resource Center, submit it here.

Bristol-Myers calls off Pixykine deal

Bristol-Myers calls off Pixykine deal

Pixykine, Immunex Corp.'s peripatetic molecule in development to boost white blood cell and platelet counts following chemotherapy, has found a new home with American Cyanamid Co.

IMNX (Seattle) had licensed rights to Pixykine outside

Read the full 389 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE